<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20240111011135&amp;v=2.18.0&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20240111011135&amp;v=2.18.0&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Thu, 11 Jan 2024 06:11:36 +0000</lastbuilddate>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Hospitalization With Cardiovascular Conditions in the Postpartum Year Among Commercially Insured Women in the U.S</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):382-384. doi: 10.1016/j.jacc.2023.11.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199715</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.006>10.1016/j.jacc.2023.11.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199715</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Nicole D Ford</dc:creator>
<dc:creator>Carla L DeSisto</dc:creator>
<dc:creator>Lindsay S Womack</dc:creator>
<dc:creator>Romeo R Galang</dc:creator>
<dc:creator>Lisa M Hollier</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Janet S Wright</dc:creator>
<dc:creator>Jean Y Ko</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hospitalization With Cardiovascular Conditions in the Postpartum Year Among Commercially Insured Women in the U.S</dc:title>
<dc:identifier>pmid:38199715</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.006</dc:identifier>
</item>
<item>
<title>Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>Gout is characterized by increased production of purines (through the pentose phosphate pathway), which is coupled with reduced renal or intestinal excretion of urate. Concurrent upregulation of nutrient surplus signaling (mammalian target of rapamycin and hypoxia-inducible factor-1a) and downregulation of nutrient deprivation signaling (sirtuin-1 and adenosine monophosphate-activated protein kinase) redirects glucose toward anabolic pathways (rather than adenosine triphosphate production), thus...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):371-381. doi: 10.1016/j.jacc.2023.10.030.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gout is characterized by increased production of purines (through the pentose phosphate pathway), which is coupled with reduced renal or intestinal excretion of urate. Concurrent upregulation of nutrient surplus signaling (mammalian target of rapamycin and hypoxia-inducible factor-1a) and downregulation of nutrient deprivation signaling (sirtuin-1 and adenosine monophosphate-activated protein kinase) redirects glucose toward anabolic pathways (rather than adenosine triphosphate production), thus promoting heightened oxidative stress and cardiomyocyte and proximal tubular dysfunction, leading to cardiomyopathy and kidney disease. Hyperuricemia is a marker (rather than a driver) of these cellular stresses. By inducing a state of starvation mimicry in a state of nutrient surplus, sodium-glucose cotransporter-2 inhibitors decrease flux through the pentose phosphate pathway (thereby attenuating purine and urate synthesis) while promoting renal urate excretion. These convergent actions exert a meaningful effect to lower serum uric acid by ≈0.6 to 1.5 mg/dL and to reduce the risk of gout by 30% to 50% in large-scale clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199714</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.030>10.1016/j.jacc.2023.10.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199714</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38199714</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.030</dc:identifier>
</item>
<item>
<title>Sudden Cardiac Death in Young Athletes: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>Athletes epitomize the healthiest segment of society. Despite this premise, sudden cardiac death may occur in apparently healthy athletes, attracting significant attention not only in the medical community but also in laypersons and media. The incidence of sudden cardiac death is variably reported, and epidemiological burden differs among cohorts. Athletes appear to be at risk of developing fatal arrhythmias when harboring a quiescent cardiac disorder. Primary cardiomyopathies, ion...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):350-370. doi: 10.1016/j.jacc.2023.10.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Athletes epitomize the healthiest segment of society. Despite this premise, sudden cardiac death may occur in apparently healthy athletes, attracting significant attention not only in the medical community but also in laypersons and media. The incidence of sudden cardiac death is variably reported, and epidemiological burden differs among cohorts. Athletes appear to be at risk of developing fatal arrhythmias when harboring a quiescent cardiac disorder. Primary cardiomyopathies, ion channelopathies, and coronary artery anomalies are prevalent causes in young individuals. Cardiac assessment of athletes can be challenging because these individuals exhibit a plethora of electrical, structural, and functional physiological changes that overlap with cardiac pathology. A diagnosis of cardiac disease in a young athlete is not necessarily an indication to terminate competition and sports participation. International guidelines, traditionally focused on disqualification of individuals with cardiac disease, have recently adopted a more liberal attitude, based on a careful assessment of the risk and on a shared-decision making approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199713</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.032>10.1016/j.jacc.2023.10.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199713</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Gherardo Finocchiaro</dc:creator>
<dc:creator>Joseph Westaby</dc:creator>
<dc:creator>Mary N Sheppard</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sudden Cardiac Death in Young Athletes: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38199713</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.032</dc:identifier>
</item>
<item>
<title>Best Oral Anticoagulant for Transcatheter Mitral Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):347-349. doi: 10.1016/j.jacc.2023.11.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199712</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.005>10.1016/j.jacc.2023.11.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199712</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:creator>Daniël C Overduin</dc:creator>
<dc:creator>Dirk Jan van Ginkel</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Best Oral Anticoagulant for Transcatheter Mitral Valve Replacement</dc:title>
<dc:identifier>pmid:38199712</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.005</dc:identifier>
</item>
<item>
<title>Comparison of Direct Oral Anticoagulants vs Vitamin K Antagonists After Transcatheter Mitral Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199711/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>CONCLUSIONS: The use of DOACs after TMVR, compared with VKAs, appears to reduce the risk of bleeding complications and decrease the length of hospital stay for patients, without a significant increase in the risk of thrombotic events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):334-346. doi: 10.1016/j.jacc.2023.10.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There is currently no established recommendation for antithrombotic treatment following transcatheter mitral valve replacement (TMVR). However, based on the analogy with surgical mitral bioprosthesis, vitamin K antagonists (VKAs) are predominantly used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to compare bleeding and thrombotic events associated with direct oral anticoagulants (DOACs) or VKAs in a prospective cohort of TMVR patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We enrolled consecutive patients who underwent transseptal TMVR using a SAPIEN family prosthesis at our center between 2011 and 2023. The primary outcome was the occurrence of bleeding. VKAs were administered to patients until October 2019, after which DOACs were prescribed. The median follow-up was 4.7 months (Q1-Q3: 2.6-6.7 months).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 156 patients were included. The mean age was 65 ± 18.5 years, and 103 patients (66%) were women. The median EuroSCORE II was 7.48% (Q1-Q3: 3.80%-12.97%). Of the participants, 20.5% received DOACs and 79.5% were treated with VKAs. The primary outcome was observed in 50 (40%) patients in the VKA group and 3 (9%) patients in the DOAC group (adjusted HR: 0.21; 95% CI: 0.06-0.74; P = 0.02). Treatment with DOAC was associated with a shorter length of hospital stay. No significant differences were found in terms of thrombotic events, major vascular complications, stroke, or death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The use of DOACs after TMVR, compared with VKAs, appears to reduce the risk of bleeding complications and decrease the length of hospital stay for patients, without a significant increase in the risk of thrombotic events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199711/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199711</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.031>10.1016/j.jacc.2023.10.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199711</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Nathan El Bèze</dc:creator>
<dc:creator>Dominique Himbert</dc:creator>
<dc:creator>Gaspard Suc</dc:creator>
<dc:creator>Eric Brochet</dc:creator>
<dc:creator>Nadine Ajzenberg</dc:creator>
<dc:creator>Audrey Cailliau</dc:creator>
<dc:creator>John Kikoïne</dc:creator>
<dc:creator>Clemence Delhomme</dc:creator>
<dc:creator>Jose Luis Carrasco</dc:creator>
<dc:creator>Phalla Ou</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Marina Urena</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparison of Direct Oral Anticoagulants vs Vitamin K Antagonists After Transcatheter Mitral Valve Replacement</dc:title>
<dc:identifier>pmid:38199711</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.031</dc:identifier>
</item>
<item>
<title>What Do We Really Know About Transcatheter Mitral Valve-in-Valve Procedures?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199710/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):331-333. doi: 10.1016/j.jacc.2023.11.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199710/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199710</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.009>10.1016/j.jacc.2023.11.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199710</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew W Sherwood</dc:creator>
<dc:creator>Amit N Vora</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>What Do We Really Know About Transcatheter Mitral Valve-in-Valve Procedures?</dc:title>
<dc:identifier>pmid:38199710</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.009</dc:identifier>
</item>
<item>
<title>Timing Surgical Mitral Valve Repair for Primary Mitral Regurgitation: An Opportunity for Sex-Guided Precision Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199709/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):313-316. doi: 10.1016/j.jacc.2023.10.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199709/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199709</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.035>10.1016/j.jacc.2023.10.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199709</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Federico Fortuni</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Timing Surgical Mitral Valve Repair for Primary Mitral Regurgitation: An Opportunity for Sex-Guided Precision Medicine</dc:title>
<dc:identifier>pmid:38199709</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.035</dc:identifier>
</item>
<item>
<title>Sex-Specific Prognosis of Left Ventricular Size and Function Following Repair of Degenerative Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>CONCLUSIONS: After mitral valve repair, women have a higher risk for all-cause mortality at lower LVESD and LVESDi and higher EF. These results support consideration of sex-specific thresholds for LVESDi in surgical decision making for patients with severe MR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):303-312. doi: 10.1016/j.jacc.2023.10.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Prior studies have demonstrated worse long-term outcomes for women after surgery for severe mitral regurgitation (MR). The current Class I indications for surgery for severe degenerative MR use cutoffs of left ventricular end-systolic dimension (LVESD) and left ventricular ejection fraction (EF) that do not account for known sex-related differences.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The primary objective of this study was to assess long-term mortality following mitral valve repair in women compared with men on the basis of preoperative left ventricular systolic dimensions and EF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients who underwent isolated mitral valve repair for degenerative MR at a single institution between 1994 and 2016 were screened. Adjusted HRs for all-cause mortality were compared according to baseline LVESD, LVESD indexed to body surface area (LVESDi), and EF for men and women.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,589 patients, 1,825 were women (40%), and after a median follow-up period of 7.2 years, 344 patients (7.5%) had died. The risk for mortality for women increased from the baseline hazard at an LVESD of 3.6 cm, whereas an inflection point for increased risk with LVESD was not evident in men. Regarding LVESDi, the risk for women increased at 1.8 cm/m<sup>2</sup> compared with 2.1 cm/m<sup>2</sup> in men. For EF, women and men had a similar inflection point (58%); however, mortality was higher for women as EF decreased.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After mitral valve repair, women have a higher risk for all-cause mortality at lower LVESD and LVESDi and higher EF. These results support consideration of sex-specific thresholds for LVESDi in surgical decision making for patients with severe MR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199708</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.033>10.1016/j.jacc.2023.10.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199708</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Bryan Q Abadie</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Sneha Vakamudi</dc:creator>
<dc:creator>A Marc Gillinov</dc:creator>
<dc:creator>Lars G Svensson</dc:creator>
<dc:creator>Leslie Cho</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sex-Specific Prognosis of Left Ventricular Size and Function Following Repair of Degenerative Mitral Regurgitation</dc:title>
<dc:identifier>pmid:38199708</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.033</dc:identifier>
</item>
<item>
<title>Clinical Utility of the Humble Exercise ECG Stress Test</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):300-302. doi: 10.1016/j.jacc.2023.10.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199707</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.036>10.1016/j.jacc.2023.10.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199707</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>John F Beltrame</dc:creator>
<dc:creator>Sarena La</dc:creator>
<dc:creator>Jessica Marathe</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Utility of the Humble Exercise ECG Stress Test</dc:title>
<dc:identifier>pmid:38199707</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.036</dc:identifier>
</item>
<item>
<title>Rethinking False Positive Exercise Electrocardiographic Stress Tests by Assessing Coronary Microvascular Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38199706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>CONCLUSIONS: In patients with ANOCA, ischemia on EST was highly specific of an underlying ischemic substrate. These findings challenge the traditional belief that EST has a high false positive rate.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 16;83(2):291-299. doi: 10.1016/j.jacc.2023.10.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exercise electrocardiographic stress testing (EST) has historically been validated against the demonstration of obstructive coronary artery disease. However, myocardial ischemia can occur because of coronary microvascular dysfunction (CMD) in the absence of obstructive coronary artery disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to assess the specificity of EST to detect an ischemic substrate against the reference standard of coronary endothelium-independent and endothelium-dependent microvascular function in patients with angina with nonobstructive coronary arteries (ANOCA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with ANOCA underwent invasive coronary physiological assessment using adenosine and acetylcholine. CMD was defined as impaired endothelium-independent and/or endothelium-dependent function. EST was performed using a standard Bruce treadmill protocol, with ischemia defined as the appearance of ≥0.1-mV ST-segment depression 80 ms from the J-point on electrocardiography. The study was powered to detect specificity of ≥91%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 102 patients were enrolled (65% women, mean age 60 ± 8 years). Thirty-two patients developed ischemia (ischemic group) during EST, whereas 70 patients did not (nonischemic group); both groups were phenotypically similar. Ischemia during EST was 100% specific for CMD. Acetylcholine flow reserve was the strongest predictor of ischemia during exercise. Using endothelium-independent and endothelium-dependent microvascular dysfunction as the reference standard, the false positive rate of EST dropped to 0%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with ANOCA, ischemia on EST was highly specific of an underlying ischemic substrate. These findings challenge the traditional belief that EST has a high false positive rate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38199706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38199706</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.034>10.1016/j.jacc.2023.10.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38199706</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Aish Sinha</dc:creator>
<dc:creator>Utkarsh Dutta</dc:creator>
<dc:creator>Ozan M Demir</dc:creator>
<dc:creator>Kalpa De Silva</dc:creator>
<dc:creator>Howard Ellis</dc:creator>
<dc:creator>Samuel Belford</dc:creator>
<dc:creator>Mark Ogden</dc:creator>
<dc:creator>Matthew Li Kam Wa</dc:creator>
<dc:creator>Holly P Morgan</dc:creator>
<dc:creator>Ajay M Shah</dc:creator>
<dc:creator>Amedeo Chiribiri</dc:creator>
<dc:creator>Andrew J Webb</dc:creator>
<dc:creator>Michael Marber</dc:creator>
<dc:creator>Haseeb Rahman</dc:creator>
<dc:creator>Divaka Perera</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rethinking False Positive Exercise Electrocardiographic Stress Tests by Assessing Coronary Microvascular Function</dc:title>
<dc:identifier>pmid:38199706</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.034</dc:identifier>
</item>
<item>
<title>Private Equity and Cardiovascular Health Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38198174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 10. doi: 10.1001/jamacardio.2023.5127. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38198174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38198174</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5127>10.1001/jamacardio.2023.5127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38198174</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Partha Sardar</dc:creator>
<dc:creator>Saurav Chatterjee</dc:creator>
<dc:creator>Zirui Song</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Private Equity and Cardiovascular Health Care</dc:title>
<dc:identifier>pmid:38198174</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5127</dc:identifier>
</item>
<item>
<title>Precision Measurement of Telomere Length as a Future Guide to Improve CVD Interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38198169/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 10. doi: 10.1001/jamacardio.2023.5006. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38198169/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38198169</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5006>10.1001/jamacardio.2023.5006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38198169</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Javier Yu Peng Koh</dc:creator>
<dc:creator>Shang Li</dc:creator>
<dc:creator>Angela S Koh</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Precision Measurement of Telomere Length as a Future Guide to Improve CVD Interventions</dc:title>
<dc:identifier>pmid:38198169</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5006</dc:identifier>
</item>
<item>
<title>Clonal Hematopoiesis and Coronary Artery Disease-A Deep Connection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38198161/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 10. doi: 10.1001/jamacardio.2023.5106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38198161/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38198161</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5106>10.1001/jamacardio.2023.5106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38198161</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>José J Fuster</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Clonal Hematopoiesis and Coronary Artery Disease-A Deep Connection</dc:title>
<dc:identifier>pmid:38198161</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5106</dc:identifier>
</item>
<item>
<title>Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 10. doi: 10.1001/jamacardio.2023.5095. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The genetic basis of coronary heart disease (CHD) has expanded from a germline to somatic genome, including clonal hematopoiesis of indeterminate potential (CHIP). How CHIP confers CHD risk in East Asian individuals, especially those with small clones (variant allele fraction [VAF] 0.5%-2%) and different genetic backgrounds, was completely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the CHIP profile in a general Chinese cohort by deep sequencing and further explore the association between CHIP and incident CHD considering germline predisposition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from 3 prospective cohorts in the project Prediction for Atherosclerotic Cardiovascular Disease Risk in China. Participants without cardiovascular disease or cancer at baseline were enrolled in 2001 and 2008 and had a median follow-up of 12.17 years extending into 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: CHIP mutations were detected by targeted sequencing (mean depth, 916×). A predefined CHD polygenic risk score (PRS) comprising 531 variants was used to evaluate germline predisposition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The main outcome was first incident CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6181 participants, the median (IQR) age was 53.83 years (45.35-62.39 years); 3082 participants (49.9%) were female, and 3099 (50.1%) were male. A total of 1100 individuals (17.80%) harbored 1372 CHIP mutations at baseline. CHIP was independently associated with incident CHD (hazard ratio [HR], 1.42; 95% CI, 1.18-1.72; P = 2.82 × 10-4) and presented a risk gradient with increasing VAF (P = 3.98 × 10-3 for trend). Notably, individuals with small clones, nearly half of CHIP carriers, also demonstrated a higher CHD risk compared with non-CHIP carriers (HR, 1.33; 95% CI, 1.02-1.74; P = .03) and were 4 years younger than those with VAF of 2% or greater (median age, 58.52 vs 62.70 years). Heightened CHD risk was not observed among CHIP carriers with low PRS (HR, 1.02; 95% CI, 0.64-1.64; P = .92), while high PRS and CHIP jointly contributed a 2.23-fold increase in risk (95% CI, 1.51-3.29; P = 6.29 × 10-5) compared with non-CHIP carriers with low PRS. Interestingly, the diversity in CHIP-related CHD risk within each PRS group was substantially diminished when removing variants in the inflammatory pathway from the PRS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38198131</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5095>10.1001/jamacardio.2023.5095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38198131</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kun Zhao</dc:creator>
<dc:creator>Xuxiang Shen</dc:creator>
<dc:creator>Hongwei Liu</dc:creator>
<dc:creator>Zhennan Lin</dc:creator>
<dc:creator>Jianxin Li</dc:creator>
<dc:creator>Shufeng Chen</dc:creator>
<dc:creator>Fangchao Liu</dc:creator>
<dc:creator>Keyong Huang</dc:creator>
<dc:creator>Jie Cao</dc:creator>
<dc:creator>Xiaoqing Liu</dc:creator>
<dc:creator>Chong Shen</dc:creator>
<dc:creator>Ling Yu</dc:creator>
<dc:creator>Yingxin Zhao</dc:creator>
<dc:creator>Liancheng Zhao</dc:creator>
<dc:creator>Ying Li</dc:creator>
<dc:creator>Dongsheng Hu</dc:creator>
<dc:creator>Jiangfeng Huang</dc:creator>
<dc:creator>Xiangfeng Lu</dc:creator>
<dc:creator>Dongfeng Gu</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population</dc:title>
<dc:identifier>pmid:38198131</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5095</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38197891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 1;9(1):4. doi: 10.1001/jamacardio.2023.3201.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38197891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38197891</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3201>10.1001/jamacardio.2023.3201</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38197891</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-10</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38197891</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3201</dc:identifier>
</item>
<item>
<title>Deficiency of Transcription Factor SP1 Contributes to Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38197258/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>CONCLUSIONS: Our study demonstrates that SP1 deficiency leads to HCM. SP1 overexpression exhibits significant therapeutic effects on both HCM mice and HCM hiPSC-CMs, suggesting that SP1 could be a potential intervention target for HCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 10. doi: 10.1161/CIRCRESAHA.123.323272. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disorder. However, the pathogenesis of HCM, especially its nongenetic mechanisms, remains largely unclear. TFs (transcription factors) are known to be involved in various biological processes including cell growth. We hypothesized that Sp1 (specificity protein 1), the first purified TF in mammals, plays a role in the cardiomyocyte growth and cardiac hypertrophy of HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cardiac-specific conditional knockout of Sp1 mice were constructed to investigate the role of SP1 in the heart. The echocardiography, histochemical experiment, and transmission electron microscope were performed to analyze the cardiac phenotypes of cardiac-specific conditional knockout of Sp1 mice. RNA sequencing, chromatin immunoprecipitation sequencing, and adeno-associated virus experiments in vivo were performed to explore the downstream molecules of SP1. To examine the therapeutic effect of SP1 on HCM, an SP1 overexpression vector was constructed and injected into the mutant allele of Myh6 R404Q/+ (<i>Myh6</i> c. 1211C>;T) HCM mice. The human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from a patient with HCM were used to detect the potential therapeutic effects of SP1 in human HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The cardiac-specific conditional knockout of Sp1 mice developed a typical HCM phenotype, displaying overt myocardial hypertrophy, interstitial fibrosis, and disordered myofilament. In addition, Sp1 knockdown dramatically increased the cell area of hiPSC-CMs and caused intracellular myofibrillar disorganization, which was similar to the hypertrophic cardiomyocytes of HCM. Mechanistically, <i>Tuft1</i> was identified as the key target gene of SP1. The hypertrophic phenotypes induced by Sp1 knockdown in both hiPSC-CMs and mice could be rescued by TUFT1 (tuftelin 1) overexpression. Furthermore, SP1 overexpression suppressed the development of HCM in the mutant allele of Myh6 R404Q/+ mice and also reversed the hypertrophic phenotype of HCM hiPSC-CMs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates that SP1 deficiency leads to HCM. SP1 overexpression exhibits significant therapeutic effects on both HCM mice and HCM hiPSC-CMs, suggesting that SP1 could be a potential intervention target for HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38197258/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38197258</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323272>10.1161/CIRCRESAHA.123.323272</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38197258</guid>
<pubDate>Wed, 10 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Fulei Zhang</dc:creator>
<dc:creator>Huixing Zhou</dc:creator>
<dc:creator>Jinfeng Xue</dc:creator>
<dc:creator>Yuemei Zhang</dc:creator>
<dc:creator>Liping Zhou</dc:creator>
<dc:creator>Junwei Leng</dc:creator>
<dc:creator>Guojian Fang</dc:creator>
<dc:creator>Yuanyuan Liu</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Hongyu Liu</dc:creator>
<dc:creator>Yahan Wu</dc:creator>
<dc:creator>Lingbin Qi</dc:creator>
<dc:creator>Ran Duan</dc:creator>
<dc:creator>Xiaoyu He</dc:creator>
<dc:creator>Yi Liu</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Jian Yang</dc:creator>
<dc:creator>Dandan Liang</dc:creator>
<dc:creator>Yi-Han Chen</dc:creator>
<dc:date>2024-01-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Deficiency of Transcription Factor SP1 Contributes to Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38197258</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323272</dc:identifier>
</item>
<item>
<title>New mechanisms-based therapies in acute ischaemic stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38195195/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 9:ehad865. doi: 10.1093/eurheartj/ehad865. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38195195/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38195195</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad865>10.1093/eurheartj/ehad865</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38195195</guid>
<pubDate>Tue, 09 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Guido Stoll</dc:creator>
<dc:creator>Michael K Schuhmann</dc:creator>
<dc:creator>Alexander M Kollikowski</dc:creator>
<dc:creator>Mirko Pham</dc:creator>
<dc:date>2024-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New mechanisms-based therapies in acute ischaemic stroke</dc:title>
<dc:identifier>pmid:38195195</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad865</dc:identifier>
</item>
<item>
<title>The '10 commandments' for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38195096/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 9:ehad881. doi: 10.1093/eurheartj/ehad881. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38195096/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38195096</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad881>10.1093/eurheartj/ehad881</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38195096</guid>
<pubDate>Tue, 09 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Katharina Schütt</dc:creator>
<dc:creator>Massimo Federici</dc:creator>
<dc:creator>Marlo Verket</dc:creator>
<dc:creator>Nikolaus Marx</dc:creator>
<dc:creator>Dirk Müller-Wieland</dc:creator>
<dc:date>2024-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The '10 commandments' for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes</dc:title>
<dc:identifier>pmid:38195096</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad881</dc:identifier>
</item>
<item>
<title>How to diagnose and treat venous congestion in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38195064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 9:ehad883. doi: 10.1093/eurheartj/ehad883. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38195064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38195064</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad883>10.1093/eurheartj/ehad883</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38195064</guid>
<pubDate>Tue, 09 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Pierpaolo Pellicori</dc:creator>
<dc:creator>David Hunter</dc:creator>
<dc:creator>Htet Htet Ei Khin</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2024-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>How to diagnose and treat venous congestion in heart failure</dc:title>
<dc:identifier>pmid:38195064</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad883</dc:identifier>
</item>
<item>
<title>Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38195054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>CONCLUSIONS: Mineralocorticoid receptor antagonists are similarly effective in preventing cardiovascular events in patients with and without HF and most likely retain their efficacy regardless of AF status. Mineralocorticoid receptor antagonists may also be moderately effective in preventing incident or recurrent AF events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 9:ehad811. doi: 10.1093/eurheartj/ehad811. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Mineralocorticoid receptor antagonists (MRAs) improve cardiovascular outcomes in a variety of settings. This study aimed to assess whether cardioprotective effects of MRAs are modified by heart failure (HF) and atrial fibrillation (AF) status and to study their impact on AF events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: MEDLINE, Embase, and Cochrane Central databases were searched to 24 March 2023 for randomized controlled trials evaluating the efficacy of MRAs as compared with placebo or usual care in reducing cardiovascular outcomes and AF events in patients with or at risk for cardiovascular diseases. Random-effects models and interaction analyses were used to test for effect modification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Meta-analysis of seven trials (20 741 participants, mean age: 65.6 years, 32% women) showed that the efficacy of MRAs, as compared with placebo, in reducing a composite of cardiovascular death or HF hospitalization remains consistent across patients with HF [risk ratio = 0.81; 95% confidence interval (CI): 0.67-0.98] and without HF (risk ratio = 0.84; 95% CI: 0.75-0.93; interaction P = .77). Among patients with HF, MRAs reduced cardiovascular death or HF hospitalization in patients with AF (hazard ratio = 0.95; 95% CI: 0.54-1.66) to a similar extent as in those without AF (hazard ratio = 0.82; 95% CI: 0.63-1.07; interaction P = .65). Pooled data from 20 trials (21 791 participants, mean age: 65.2 years, 31.3% women) showed that MRAs reduce AF events (risk ratio = 0.76; 95% CI: 0.67-0.87) in both patients with and without prior AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mineralocorticoid receptor antagonists are similarly effective in preventing cardiovascular events in patients with and without HF and most likely retain their efficacy regardless of AF status. Mineralocorticoid receptor antagonists may also be moderately effective in preventing incident or recurrent AF events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38195054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38195054</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad811>10.1093/eurheartj/ehad811</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38195054</guid>
<pubDate>Tue, 09 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Alireza Oraii</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Krzysztof Kowalik</dc:creator>
<dc:creator>Avinash K Pandey</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Jorge A Wong</dc:creator>
<dc:creator>David Conen</dc:creator>
<dc:creator>William F McIntyre</dc:creator>
<dc:date>2024-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials</dc:title>
<dc:identifier>pmid:38195054</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad811</dc:identifier>
</item>
<item>
<title>Tackling cardiovascular healthcare disparities for LGBTQIA+ population: a call to action in the European Society of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38195053/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240111011135&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 9:ehad882. doi: 10.1093/eurheartj/ehad882. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38195053/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240111011135&v=2.18.0">38195053</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad882>10.1093/eurheartj/ehad882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38195053</guid>
<pubDate>Tue, 09 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Alexander Kharlamov</dc:creator>
<dc:creator>Nigel Sherriff</dc:creator>
<dc:creator>Christian Delles</dc:creator>
<dc:creator>Pim van der Harst</dc:creator>
<dc:date>2024-01-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tackling cardiovascular healthcare disparities for LGBTQIA+ population: a call to action in the European Society of Cardiology</dc:title>
<dc:identifier>pmid:38195053</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad882</dc:identifier>
</item>




























</channel>
</rss>